@article {Breyssedmd.119.089326, author = {Daniel H Breysse and Ryan M Boone and Cameron M Long and Miranda E Merrill and Christopher M Schaupp and Collin C White and Terrance J Kavanagh and Edward E Schmidt and Gary Frederic Merrill}, title = {Carbonyl reductase 1 plays a significant role in converting doxorubicin to cardiotoxic doxorubicinol in mouse liver, but the majority of the doxorubicinol-forming activity remains unidentified}, elocation-id = {dmd.119.089326}, year = {2020}, doi = {10.1124/dmd.119.089326}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {Doxorubicin is a widely used cancer therapeutic, but its effectiveness is limited by cardiotoxic side effects. Evidence suggests cardiotoxicity is due not to doxorubicin, but rather its metabolite, doxorubicinol. Identification of the enzymes responsible for doxorubicinol formation is important in developing strategies to prevent cardiotoxicity. In this study, the contributions of three murine candidate enzymes to doxorubicinol formation were evaluated: carbonyl reductase 1 (Cbr1), carbonyl reductase 3 (Cbr3), and thioredoxin reductase 1 (Tr1). Analyses with purified proteins revealed that all three enzymes catalyzed doxorubicin-dependent NADPH oxidation, but only Cbr1 and Cbr3 catalyzed doxorubicinol formation. Doxorubicin-dependent NADPH oxidation by Tr1 was likely due to redox cycling. Subcellular fractionation results showed that doxorubicin-dependent redox cycling activity was primarily microsomal, whereas doxorubicinol-forming activity was exclusively cytosolic, as were all three enzymes. An immunoclearing approach was used to assess the contributions of the three enzymes to doxorubicinol formation in the complex milieu of the cytosol. Immunoclearing Cbr1 eliminated 25\% of the total doxorubicinol-forming activity in cytosol, but immunoclearing Cbr3 had no effect, even in Tr1 null livers that overexpressed Cbr3. The immunoclearing results constituted strong evidence that Cbr1 contributed to doxorubicinol formation in mouse liver, but that enzymes other than Cbr1 also played a role, a conclusion supported by ammonium sulfate fractionation results, which showed that doxorubicinol-forming activity was found in fractions that contained little Cbr1. In conclusion, the results show that Cbr1 accounts for 25\% of the doxorubicinol-forming activity in mouse liver cytosol but that the majority of the doxorubicinol-forming activity remains unidentified.SIGNIFICANCE STATEMENT Earlier genetic and drug inhibition results suggested Cbr1 plays a dominant role in converting chemotherapeutic doxorubicin to cardiotoxic doxorubicinol, but a new immunoclearing approach described herein shows that Cbr1 accounts for only 25\% of the doxorubicinol-forming activity in mouse liver cytosol, that two other candidate enzymes – Cbr3 and Tr1 – play no role, and that the majority of the activity remains unidentified. The results suggest that targeting Cbr1 is necessary but not sufficient to eliminate doxorubicinol-associated cardiotoxicity; identification and targeting of the additional doxorubicinol-forming activity is an important next challenge.}, issn = {0090-9556}, URL = {https://dmd.aspetjournals.org/content/early/2020/01/18/dmd.119.089326}, eprint = {https://dmd.aspetjournals.org/content/early/2020/01/18/dmd.119.089326.full.pdf}, journal = {Drug Metabolism and Disposition} }